Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,810,000 shares, a decrease of 47.4% from the December 15th total of 3,440,000 shares. Based on an average daily trading volume, of 3,970,000 shares, the short-interest ratio is currently 0.5 days. Currently, 2.3% of the shares of the company are short sold.

Institutional Trading of Chimerix

Institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. grew its position in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Chimerix in the second quarter valued at $137,000. Finally, Valeo Financial Advisors LLC raised its holdings in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares during the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Trading Up 1.2 %

NASDAQ CMRX traded up $0.04 on Tuesday, reaching $3.35. The company’s stock had a trading volume of 2,100,478 shares, compared to its average volume of 1,505,649. The firm has a market cap of $301.29 million, a PE ratio of -3.56 and a beta of 0.36. Chimerix has a 52 week low of $0.75 and a 52 week high of $3.80. The business has a 50-day moving average price of $2.06 and a 200 day moving average price of $1.31.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Monday, December 30th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.